Recent Updates — MRKR

Marker Therapeutics announced it received a $2.6 million Orphan Products Clinical Trials grant from the U.S. Food and Drug Administration (FDA). The non-dilutive funding supports a Phase 1 clinical study of its lead investigational MAR-T cell therapy, MT-601, in patients with locally advanced unresectable pancreatic cancer. This competitive award validates the scientific rationale for the company's multi-antigen recognizing T cell platform and follows prior support from the NIH and CPRIT. The company anticipates initiating the clinical study in the first quarter of 2027.

Marker Therapeutics is a clinical-stage immuno-oncology company specializing in the development of next-generation, non-genetically modified T cell-based immunotherapies for hematological malignancies and solid tumors.